Daniel Lauchheimer
Contributor since: 2012
Latest Articles
Has Glasses Off Come Up With The Next Great App?
Unpacking Microsoft's Recent Moves
Mobile Strategy: Winners And Losers
Peter Thiel's Error
Skyline Medical: FDA Approved, Little Competition And A Lot Of Room To Run
Does Exact Sciences' $1B Valuation Foreshadow A Bright Future For TrovaGene?
TrovaGene: A Stock Filled With Freebies
DNA Giant Illumina's Newest Partnership
If Chipotle Goes Down, It Will Go Down Hard
Big Opportunities For Implant Sciences: An Interview With The CEO
Mall REIT Analysis And An Unexpected Tesla Connection
Did Yahoo Underpay For Tumblr?
Prolor Biotech Buyout: Is The Opko Bear Case Now Dead?
Different Threats, Different Solutions, Many Ways To Make Money
Untangling Vornado Realty And Finding Gold
Protect Your Country, Protect Your Portfolio
Prolor Biotech: Unlimited Upside?
BioDrain Medical Is About To Clean Up: An Interview With CEO Josh Kornberg
Sizing Up The Single Family Home Sector
Longer Lasting Drugs Make For Longer Lasting Profits
Zuckerman Out, Thomas In: What Boston Properties Latest Move Means
Adopt Prolor's Orphan Drug And Reward Your Portfolio
Radioactive Growth In Nuclear Medicine: An Overview
Stryker Corporation: Specific M&A Predictions
Equties Will Rise: 6 Solid Stock Alternatives To The SPY
Has The TSA Opened The Door For Implant Sciences To Make $500mm And Maybe More?
CapLease: Very Cheap
Chesapeake Energy: Still Not Worth The Risk
Knight Capital: What's Next
New York City Has 9.8% Unemployment: Office REITs Will Benefit
Samsung Doesn't Think Google Will Give Motorola Preferential Android Treatment
Residential REITs With Highest New York City Exposure